Dimethyl Fumarate Treatment in Patients with Moderate-to-Severe Psoriasis: A 52-week Real-life Study

Acta Derm Venereol. 2023 Mar 28:103:adv4526. doi: 10.2340/actadv.v103.4526.
No abstract available

MeSH terms

  • Dermatologic Agents* / adverse effects
  • Dimethyl Fumarate / adverse effects
  • Humans
  • Psoriasis* / chemically induced
  • Psoriasis* / diagnosis
  • Psoriasis* / drug therapy
  • Treatment Outcome

Substances

  • Dimethyl Fumarate
  • Dermatologic Agents